Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
134
resultados
Última actualización
21/08/2025 [07:03:00]
Resumen de: MX2025004342A
The invention relates to pharmaceutical product comprising a polynucleotide for use in the prevention or treatment of a SARS-CoV-2 virus infection wherein said SARS-CoV-2 virus is not a Wuhan wild-type SARS-CoV-2 virus. The polynucleotide encodes an attenuated human coronavirus or a fragment thereof, wherein the polynucleotide comprises at least 20 one-to-stop codons, wherein a one-to-stop codon is i) a different but synonymous codon compared to the corresponding codon in a natural human coronavirus genome and ii) differs by one nucleotide from a STOP codon.
Resumen de: EP4603477A1
The invention relates to an inhibitor targeting the coronavirus accessory protein ORF9b of formula I, or a pharmaceutical salt thereof, wherein the meanings for the various substituents are as disclosed in the description. Furthermore, the invention relates to its use as a medicament, particularly for the treatment of the hyperinflammation induced by highly pathogenic coronaviruses such as SARS-CoV-2, SARS-CoV or MERS.
Resumen de: US2025257099A1
Described are lipopeptides that inhibit coronavirus fusion to a host cell. Thus a therapeutic for treating or preventing the common cold is described along with methods of inhibiting and/or treating an alphacoronavirus infection. The lipopeptides comprise a peptide unit comprising an amino acid sequence having a high degree of sequence identity to a sequence from the C-terminal heptad repeat of a betacoronavirus S protein, such as that of SARS-CoV-2.
Resumen de: US2025255842A1
The present invention concerns a treatment of Long COVID-19 by using specialized pro-resolving lipid mediators (SPM) or their active precursors. optionally in combination with a non-steroidal anti-inflammatory drug.
Resumen de: US2025255954A1
Disclosed herein is a new method referred to as Conformational Shifting by Distance and Volume Analysis (CS-DVA) which can be employed to change the dynamics of multi-state glycoproteins for altered immune responses. Also disclosed are stabilized spike antigens and methods of use thereof for SARS-COV-2 vaccines.
Resumen de: US2025258173A1
The present invention provides a method of immunologically detecting SARS-CoV-2, the method comprising detecting a SARS-CoV-2 N protein in a specimen taken from a subject by using the following antibodies (1) and (2):(1) a first antibody to a first epitope in a 306th to 339th amino acid region in the SARS-CoV-2 N protein, and(2) a second antibody to a second epitope in a 365th to 419th amino acid region in the SARS-CoV-2 N protein.
Resumen de: US2025257100A1
Disclosed are peptides comprising a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; SARS-CoV-2 antigen; and a trimerization domain. Disclosed are peptide complexes comprising three peptides, wherein each of the three peptides comprises a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; SARS-CoV-2 antigen; and a trimerization domain. Disclosed are compositions comprising any of the disclosed peptides or peptide complexes. Disclosed are methods for eliciting a protective immune response against SARS-CoV-2 comprising administering to a subject an effective amount of one or more of the compositions disclosed herein. Disclosed are methods of treating a subject exposed to SARS-CoV-2 or at risk of being exposed to SARS-CoV-2 comprising administering to a subject an effective amount of one or more of the compositions disclosed herein.
Resumen de: WO2025170898A1
The present disclosure relates to compounds that act as inhibitors against the attachment of the SARS-CoV-2 virus, pharmaceutical formulations thereof, and methods of using the compounds to prevent and treat diseases associated with the SARS-CoV-2 virus.
Resumen de: WO2025169929A1
The present invention provides a method for treating a sequela of an infection by a SARS-CoV-2 virus, the method including administering an inhibitor of an RNA-dependent RNA polymerase (RdRp) of the virus to a patient who needs the treatment. Also provided are: a method for screening for a therapeutic agent for a sequela of an infection by the virus; and a model mouse useful for the method.
Resumen de: WO2025168689A1
The disclosure relates to treating and preventing coronavirus infections, in particular SARS-CoV-2. The disclosure also relates to treating or preventing cardiovascular symptoms associated with coronavirus infections, including blood clotting, heart attack, stroke, pulmonary embolism and/or thrombosis. The disclosure further relates to antibodies which may be used in such methods.
Resumen de: WO2025170972A1
The present disclosure relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
Resumen de: WO2025171130A1
The present disclosure relates to compounds of Formula I and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
Resumen de: WO2024074651A1
This application relates to novel compounds and their use as SARS-CoV-2 Main Protease (Mpro) inhibitors. Compounds described herein may be useful in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2: Mpro. The application is also directed to pharmaceutical compositions comprising these compounds and the manufacture and use of these compounds and compositions in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2: Mpro. The compounds and compositions may be useful in preventing death or complications arising due to chronic underlying conditions or comorbidities in patients infected with SARS- CoV-2 and related viruses.
Resumen de: WO2024074848A1
Compounds of formula (I) are disclosed: or a salt, solvate or tautomer thereof, wherein; MPL comprises a SARS-CoV-2 main protease ligand, X comprises a divalent exit vector; Xi comprises a divalent exit vector; a and b are independently selected from 1 or 2; L comprises a divalent linker, and UL comprises an E3 ubiquitin ligase ligand. Also disclosed are pharmaceutical compositions comprising such compounds or combinations, and methods and reagents using the compounds. Compounds may have therapeutic uses and uses in research.
Resumen de: GB2638106A
A diagnostic device for detecting a first member of a reporter-analyte pair comprising: an inlet for receiving a liquid, biological sample; a porous membrane element comprising a detection portion, the detection portion being in liquid communication with the inlet, wherein the detection portion comprises a second member of the reporter-analyte pair and a variant of the second member of the reporter-analyte pair immobilisable thereon, and wherein an interaction between the first member of the reporter-analyte pair and the second member of the reporter-analyte pair is separately detectable from an interaction between the first member of the reporter-analyte pair and the variant of the second member of the reporter-analyte pair. Preferably the second members of the pair are immobilised at discrete sites and the device further comprises a control. Optionally the second membrane is a biological antigen such as a protein or polypeptide and the first member an antibody. Optionally the antigen is a COVID-19 S1 spike protein.
Resumen de: WO2024074849A1
Compounds of formula (I) are disclosed: or a salt, solvate or tautomer thereof, wherein; PLL comprises a SARS-CoV-2 papain-like protease ligand, X comprises a divalent exit vector; X1 comprises a divalent exit vector; a and b are independently selected from 1 or 2; L comprises a divalent linker, and UL comprises an E3 ubiquitin ligase ligand. Also disclosed are pharmaceutical compositions comprising such compounds or combinations, and methods and reagents using the compounds. Compounds may have therapeutic uses and uses in research.
Resumen de: MX2025003937A
The present invention features crystalline forms of Compound I, including polymorphs and pseudopolymorphs, which are useful in the preparation of pharmaceutical compositions.
Resumen de: US2025248965A1
Compounds for use against a viral infection The invention relates to hexahydronaphthalen-2-one derivatives, such as petasol, petasin and isopetasol, for use in the prevention or the treatment of viral infections. In particular compounds extracted from Darksidea spp. are provided for use in the treatment of SARS-CoV-2 infection.
Resumen de: US2025250647A1
Coronavirus genomes comprising non-native SARS-CoV-2 RNAs having genetically inactivated spike (S), envelope (E), and membrane (M) genes, and optionally a genetically inactivated nucleocapsid (NP) gene, are provided. Such coronavirus genomes further include a reporter gene and a marker gene, and substitutions within a non-structural protein 1 (Nsp1) gene (such as K164A and H165A). Also provided are cells containing the coronavirus genomes, for example, stable cell clones having the isolated non-native coronavirus genome autonomously replicating inside the cells. Also provided are methods of using such cells, for example, methods of identifying anti-viral compounds, such as quantitative high-throughput screening methods that can optionally be performed in a biosafety level 2 (BSL2) laboratory.
Resumen de: US2025250312A1
A bifunctional peptide is provided, the bifunctional peptide comprising a virus binding moiety and a mucin binding moiety covalently bound to the virus binding moiety. The virus binding moiety is chosen from peptides binding to SARS-CoV-2, to influenza A, to influenza B, to rhinoviruses and other enteroviruses, to human parainfluenza virus, and/or to metapneuvirus. The mucin binding moiety is chosen from lectins such as trefoil factor 3.
Resumen de: WO2025164815A1
The present invention relates to a novel peptide having binding affinity to ACE2 and uses thereof and, more specifically, to: a peptide represented by any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 4, and having binding affinity to ACE2; a nanocarrier and a drug complex, each comprising the peptide; and a pharmaceutical composition for preventing or treating COVID-19, comprising the peptide, the nanocarrier, or the drug complex. The novel peptide according to the present invention can be used to increase the COVID-19 therapeutic effect through specific binding to ACE2-expressing cells.
Resumen de: US2025250254A1
A compound represented by formula (I) or an optical isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof are provided. In formula (I), R1-R17 are each independently selected from hydrogen and deuterium, R18 and R19 are hydrogen, and R1-R19 are not simultaneously hydrogen. The deuterated compound and the salt, hydrate or solvate thereof have excellent metabolic stability and pharmacokinetic properties, and can be used in the manufacture of tubulin inhibitors, anti-cancer drugs, antiviral drugs, and drugs for the treatment of novel coronavirus pneumonia.
Resumen de: AU2025205555A1
Disclosed herein are nucleic acid molecules encoding a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) spike antigen, SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a SARS-CoV-2 infection in a subject. Disclosed herein are nucleic acid molecules encoding a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) spike antigen, SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a SARS-CoV-2 infection in a subject. ul u l i s c l o s e d h e r e i n a r e n u c l e i c a c i d m o l e c u l e s e n c o d i n g a e v e r e c u t e e s p i r a t o r y y n d r o m e c o r o n a v i r u s ( - o - ) s p i k e a n t i g e n , - o - s p i k e a n t i g e n s , i m m u n o g e n i c c o m p o s i t i o n s , a n d v a c c i n e s a n d t h e i r u s e i n i n d u c i n g i m m u n e r e s p o n s e s a n d p r o t e c t i n g a g a i n s t o r t r e a t i n g a - o - i n f e c t i o n i n a s u b j e c t
Resumen de: WO2025163362A1
The proposed invention, which combines cellulose acetate nanofibers with hyssop essential oil, offers a unique approach by integrating both advanced filtration technology and natural antiviral agents. This dual functionality sets it apart from existing patents, potentially providing enhanced protection against airborne pathogens while maintaining breathability and comfort.
Nº publicación: US2025249088A1 07/08/2025
Solicitante:
GENEONE LIFE SCIENCE INC [KR]
GENEONE LIFE SCIENCE, INC
Resumen de: US2025249088A1
Provided herein is an immunogenic composition comprising a synthetic antigen to COVID spike proteins, particularly the chimeric intermediate structure C-A Complex. Also disclosed herein is a method of preventing and/or treating a COVID infection in a subject in need thereof, by administering the immunogenic composition to the subject.
BOPI
Sede Electrónica
